Bone mineral disease in children after renal transplantation in steroid-free and steroid-treated patients - A prospective study

Pediatric Transplantation

Volumn 15, Issue 2, 2011, Pages 205-213

  Grenda, Ryszard ^a   Karczmarewicz, Elzbieta ^a   Rubik, Jacek ^a   Matusik, Halina ^a   Płudowski, Paweł ^a   Kiliszek, Małgorzata ^a   Piskorski, Jarosław ^b  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^b UNIVERSITY OF ZIELONA GÓRA   (Poland)

Author keywords

bone disease; prophylaxis; renal transplantation; steroid minimization

Indexed keywords

ALFACALCIDOL; AMINO TERMINAL TELOPEPTIDE; CALCIFEDIOL; CALCIUM; COLLAGEN; CYCLOSPORIN A; DACLIZUMAB; IBANDRONIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARATHYROID HORMONE; PHOSPHATE; PREDNISONE; PROCOLLAGEN 1 AMINO TERMINAL PROPEPTIDE; RAPAMYCIN; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BONE DENSITY; BONE DISEASE; BONE MINERAL; CALCIUM BLOOD LEVEL; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSIS; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FOLLOW UP; GENDER; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUMBAR SPINE; OSTEOLYSIS; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCHOOL CHILD; STEROID THERAPY;

ADMINISTRATION, ORAL; ADOLESCENT; AGE FACTORS; ANALYSIS OF VARIANCE; BONE DEMINERALIZATION, PATHOLOGIC; BONE DENSITY; CALCIFEDIOL; CHILD; COHORT STUDIES; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEX FACTORS; TREATMENT OUTCOME;

EID: 79951666812     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2010.01448.x     Document Type: Article

References (42)

1. Cvijetic S, Slavitzek J, Karacic I, Puretic Z, Kes P,. Bone density in renal transplant recipients and in patients with chronic kidney disease: A follow-up study in children and adolescents. Clin Nephrol 2010: 73: 197-203.
2. Feber J, Cochat P, Braillon P,. Bone mineral density in children after renal transplantation. Pediatr Nephrol 2000: 14: 654-657. (Pubitemid 30394447)
3. Saland JM, Goode ML, Haas DL, Romano TA, Seikaly MG,. The prevalence of osteopenia in pediatric renal allograft varies with the method of analysis. Am J Transplant 2001: 1: 243-250. (Pubitemid 33674168)
4. El-Husseini AA, Al-Agroudy AE, Wafa EW, Mohsen T, Sobh MA, Ghoneim MA,. Bone mineral density in live related kidney transplant children and adolescents. Int Urol Nephrol 2004: 36: 95-100. (Pubitemid 38864817)
5. Palmer SC, Stripolli GF, McGregor DO,. Interventions for preventing bone disease in kidney transplant recipients: A systematic review of randomized controlled trials. Am J Kidney Dis 2005: 45: 638-649. (Pubitemid 40460752)
6. Palmer SC, McGregor DO, Stripolli GF, Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev 2007, 3:CD005015
7. El-Husseini AA, Al-Agroudy AE, El-Sayed MF, Sobh MA, Ghoneim MA,. Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatr Transplant 2004: 8: 357-361. (Pubitemid 39062119)
8. Collaud S, Staub-Zahner T, Trombetti A, et al. Increase of bone mineral density after successful parathyreidectomy for tertiary hyperparathyroidism after renal transplantation. World J Surg 2008: 32: 1795-1801.
9. Grenda R, Watson A, Trompeter R, et al. A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: The TWIST study. Am J Transplant 2010: 10: 828-836.
10. Pyon EY,. Once-monthly ibandronate for postmenopausal osteoporosis: Review of a new dosing regimen. Clin Ther 2006: 28: 4.
11. ICH harmonized tripartite guidelines for good clinical practice: E6(R1). 2006:.
12. W orld M edical A ssociation. Declaration of Helsinki: ethical principles for medical research involving human subjects.
13. Płudowski P, Matusik H, Olszaniecka M, et al. Reference values for the indicators of skeletal and muscular status of healthy Polish children. J Clin Densitom 2005: 8: 164.
14. Płudowski P, Jaworski M,. Safety and quality standards in bone status assessment by dual energy X-ray absorptiometry. Standardy Med (Polish) 2008: 5: 201-205.
15. Gordon CM, Bachrach LK, Carpenter TO, et al. Dual energy X-ray absorptiometry interpretation and reporting in children and adolescents: The 2007 ISCD Pediatric Official Positions. J Clin Densitom 2008: 11: 43-58. (Pubitemid 351602187)
16. Bishop N, Braillon P, Burnham J, et al. Dual energy X-ray absorptiometry assessment in children and adolescents with diseases that may affect the skeleton: The 2007 ISCD Pediatric Official Positions. J Clin Densitom 2008: 11: 29-42. (Pubitemid 351602186)
17. Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009: 20: 629-637.
18. Yan J, Fine JP,. Estimating equations for associating structures. Stat Med, 2004: 23: 859-880.
19. Acott PD, Crocker JFS, Wong JA,. Decreased bone mineral density in the pediatric renal transplantation in children. Pediatr Transplant 2003: 7: 358-363. (Pubitemid 37295941)
20. Torregosa JV, Campistol JM, Montesinos M, Pons F, Martinez de Osaba M,. Evolution of bone mineral density after renal transplantation; related factors. Nephrol Dial Transplant 1995: 10: 111-113.
21. Grotz WH, Mundinger FA, Rasenack J, et al. Bone mineral loss after kidney transplantation; a longitudinal study in 115 graft recipients. Nephrol Dial Transplant 1995: 10: 2096-2100.
22. Casez JP, Lippuner K, Horber FF, Montadon A, Jaeger P,. Changes in bone mineral density over 18 months following kidney transplantation: The respective roles of prednisone and parathyroid hormone. Nephrol Dial Transplant 2002: 17: 1318-1326. (Pubitemid 34812080)
23. Marcen R, Caballero C, Pascual J, et al. Lumbar bone mineral density in renal patients on neoral and tacrolimus: A 4 years study. Transplantation 2006: 81: 826-831.
24. Hamiwka LA, Hanna M, Midgley JP, Wade AW, Grisaru S,. Areal and volumetric bone mineral density changes after renal transplantation in children: A longitudinal study. Transplant Proc 2008: 40: 1404-1406. (Pubitemid 351853161)
25. Ellis EN, Floyd-Gimon DM, Berry PL, et al. Risk factors for bone mineral density loss in pediatric renal transplant recipients. Pediatr Transplant 2000: 4: 146-150. (Pubitemid 30316826)
26. Sanchez CP, Salusky IB, Kuizon BD, et al. Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int 1998: 53: 1358-1364. (Pubitemid 28316899)
27. Reusz GS, Szabo AJ, Peter F, et al. Bone metabolism and mineral density following renal transplantation. Arch Dis Child 2000: 83: 146-151. (Pubitemid 30670427)
28. Klaus G, Paschen C, Wüster C, et al. Weight-/height-related bone mineral density is not reduced after renal transplantation. Pediatr Nephrol 1998: 12: 343-348. (Pubitemid 28318941)
29. Lukert BP, Raisz LG,. Glucocorticoid-induced osteoporosis: Pathogenesis and treatment. Ann Int Med 1990: 112: 352-364.
30. Goffin E, Devogelaer JP, Lalaoui A, et al. Tarcolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. Transpl Int 2002: 15: 73-80.
31. Cueto-Manziano AM, Konel S, Crowley V, et al. Bone histopathology and densitometry comparison between cyclosporine monotherapy and prednisolone plus azathioprine dual immunosuppression in renal transplant recipients. Transplantation 2003: 75: 2053-2058. (Pubitemid 36793292)
32. Westeel FP, Mazouz H, Ezaitouni E, et al. Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation. Kidney Int 2000: 58: 1788-1796.
33. De Sevaux RG, Hoistma AJ, Van Hoof HJ, Corstens FJ, Wetzels JF,. Abnormal vitamin D metabolism and loss of bone mass after renal transplantation. Nephron Clin Pract 2003: 93: C21-C28.
34. Coco M, Glicklich D, Faugere MC, et al. Prevention of bone loss in renal transplant recipients; a prospective randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003: 14: 2669-2676. (Pubitemid 37169355)
35. Fan S, Almond MK, Ball E, Evans K, Cunningham J,. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 2000: 57: 684-690. (Pubitemid 30430662)
36. Grotz W, Nagel C, Poeschel D, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 2001: 12: 1530-1537. (Pubitemid 32666337)
37. Kovac D, Lindie J, Kandus A, Bren AF,. Prevention of bone loss with alendronate in kidney transplant recipients. Transplantation 2000: 70: 1542-1543.
38. Nowacka-Cieciura E, Cieciura T, Baczkowska T, et al. Bisphosphonates are effective prophylactic of early bone loss after renal transplantation. Transplant Proc 2006: 38: 165-167.
39. Mitterbauer C, Schwarz C, Haas C, Oberbauer R,. Effect of bisphosphonates on bone loss in the first year after renal transplantation-a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2006: 21: 2275-2281. (Pubitemid 44295056)
40. Rauch F, Plotkin H, Travers R, et al. Osteogenesis imperfecta types I, III, and IV: Effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 2003: 88: 986-992. (Pubitemid 36337744)
41. Bachrach LK, Ward LM,. Clinical review: Bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009: 94: 400-409.
42. Ziólkowska H, Panczyk-Tomaszewska M, Debinski A, Polowiec Z, Sawicki A, Sieniawska M,. Bone biopsy results and serum bone turnover parameters in uremic children. Acta Paediatr 2000: 89: 666-671. (Pubitemid 30624909)